Orchestra BioMed Holdings (OBIO) Net Cash Flow (QoQ) (2021 - 2026)
Analysis
Orchestra BioMed Holdings (OBIO) Net Cash Flow (QoQ) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.86% |
| Mar 31, 2026 | 13.64% |
| Dec 31, 2025 | -131.47% |
| Sep 30, 2025 | 5,701.25% |
| Jun 30, 2025 | 110.25% |
| Mar 31, 2025 | -17.02% |
| Dec 31, 2024 | -276.74% |
| Sep 30, 2024 | 386.38% |
| Jun 30, 2024 | 105.38% |
| Mar 31, 2024 | -163.02% |
| Dec 31, 2023 | 330.16% |
| Sep 30, 2023 | 216.75% |
| Jun 30, 2023 | -109.92% |
| Mar 31, 2023 | 98.59% |
| Dec 31, 2022 | -673.81% |
| Sep 30, 2022 | -112.85% |
| Jun 30, 2022 | 300.36% |
| Mar 31, 2022 | 67,355.07% |
| Dec 31, 2021 | 77.47% |
| Sep 30, 2021 | -227.03% |